Why the study?
Right heart remodeling in chronic pulmonary hypertension causes ECG abnormalities, but the resolution of ECG markers of RVH following acute versus long-term hemodynamic improvement required investigation.
Does acute and long-term hemodynamic improvement resolve ECG markers of right ventricular hypertrophy in patients with pulmonary hypertension?
Does acute and long-term hemodynamic improvement resolve ECG markers of right ventricular hypertrophy in patients with pulmonary hypertension?
Improvement in ECG parameters of right ventricular hypertrophy following effective treatment of chronic pulmonary hypertension requires extended time rather than just acute hemodynamic relief.
ECG RVH markers may not reflect acute PH relief; leaves open their utility for tracking long-term treatment response.
Background The remodeling of the right heart in patients with chronic pulmonary hypertension (cPH) is associated with the appearance of electrocardiographic (ECG) abnormalities. We investigated the resolution of ECG markers of right ventricular hypertrophy (RVH) caused by acute and long‐term hemodynamic improvement. Methods Twenty‐nine (29) patients with chronic thromboembolic pulmonary hypertension (CTEPH) and seven patients with pulmonary arterial hypertension (PAH) were included in the analysis. Patients with CTEPH achieved a significant long‐term hemodynamic improvement following the treatment with balloon pulmonary angioplasty (BPA); all the patients with PAH reported significant acute hemodynamic relief after a single inhalation of iloprost, fulfilling the criteria of responder. Standard 12‐lead ECG was performed before and after intervention. Results The interval between baseline and control ECG in CTEPH and PAH groups was 28 (IQR: 17–36) months and 15 min (IQR: 11–17), respectively. Despite similar hemodynamic improvement in both groups, only the CTEPH group presented significant changes in most analyzed ECG parameters: T‐wave axis ( p = .002), QRS‐wave axis ( p = .012), P‐wave amplitude ( p < .001) and duration in II ( p = .049), R‐wave amplitude in V 1 ( p = .017), R:S ratio in V 1 ( p = .046), S‐wave amplitude in V 5 ( p = .004), R‐wave amplitude in V 5 ( p = .044), R:S ratio in V 5 ( p = .004), S‐wave amplitude in V 6 ( p = .026), R‐wave amplitude in V 6 ( p = .01), and R‐wave amplitude in aVR ( p = .031). In patients with PAH, significant differences were found only for P wave in II (duration: p = .035; amplitude: p = .043) and QRS axis ( p = .018). Conclusions The effective treatment of cPH ensures improvement in ECG parameters of RVH, but it requires extended time.
No takes yet. Share an insight, caveat, or question.
Piłka et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: